永安药业(002365) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥192,899,136.83, a decrease of 14.03% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2024 was ¥9,370,026.15, an increase of 196.61% year-on-year[3]. - The net profit excluding non-recurring items for Q3 2024 was ¥1,511,388.93, up 106.94% compared to the same period last year[3]. - Net profit for the third quarter was CNY 30,160,985.94, a decrease of 67.42% compared to the previous year[7]. - The company's total revenue for the current period is RMB 618,715,718.75, a decrease of 22.8% compared to RMB 802,818,715.84 in the previous period[15]. - The company's net profit for the current period is not explicitly stated, but the decrease in revenue and operating costs suggests a potential impact on profitability[15]. - The net profit for Q3 2024 was CNY 58,799,695.42, an increase from CNY 41,086,189.05 in Q3 2023, representing a growth of approximately 43.3%[16]. - The total operating profit for Q3 2024 was CNY 69,149,902.30, compared to CNY 75,082,218.20 in Q3 2023, indicating a decline of about 7.9%[16]. Cash Flow and Assets - The company's cash flow from operating activities for the year-to-date was ¥93,294,328.83, down 52.01% year-on-year[3]. - Operating cash flow decreased by 52.01% to CNY 93,294,328.83 due to increased tax payments and the expiration of a business cooperation agreement[7]. - The net increase in cash and cash equivalents was CNY -101,078,767.21, representing a 249.67% decline year-over-year[7]. - The company's cash and cash equivalents decreased to RMB 193,149,436.01 from RMB 326,171,803.22, representing a decline of 40.7%[12]. - The cash flow from operating activities netted CNY 93,294,328.83, a decrease from CNY 194,396,155.83 in Q3 2023, showing a decline of about 52.0%[18]. - The cash and cash equivalents at the end of Q3 2024 stood at CNY 193,149,436.01, down from CNY 245,795,419.71 at the end of Q3 2023, a decrease of about 21.4%[19]. Investment and Income - The company reported a significant increase in investment income of 67.84% year-on-year, totaling ¥28,707,327.09[6]. - The company's investment income from joint ventures and associates was CNY 3,984,108.33, significantly higher than CNY 1,502,888.96 in Q3 2023, representing an increase of approximately 165.7%[16]. - Investment activities resulted in a net cash outflow of CNY 145,855,877.36, slightly improved from a net outflow of CNY 160,648,157.01 in Q3 2023[19]. Inventory and Assets - The company experienced a 31.79% increase in inventory, reaching ¥92,119,067.35 due to increased product stock[6]. - The total assets at the end of Q3 2024 were ¥2,277,907,749.53, a decrease of 2.95% from the end of the previous year[3]. - The company's total assets decreased to RMB 2,277,907,749.53 from RMB 2,347,138,093.66, a reduction of 2.9%[14]. - The inventory increased to RMB 92,119,067.35, up 32.0% from RMB 69,895,984.49 at the beginning of the period[12]. Shareholder and Stock Information - The top shareholder, Chen Yong, holds 21.54% of the shares, totaling 63,468,000 shares[8]. - The company repurchased 3,442,350 shares, accounting for 1.17% of total share capital, with a total transaction amount of CNY 24,170,198.50[10]. - The company adjusted its share repurchase price ceiling from CNY 8.00 to CNY 7.90 per share effective from July 5, 2024[10]. Legal and Operational Developments - The company faced a patent infringement lawsuit in the U.S. but won the case, with ongoing monitoring of the situation[10]. - The company is expanding its production capacity with a project to produce 40,000 tons of taurine food additives annually[10]. - The company is in the final stages of expanding its annual production capacity for taurine food additives to 40,000 tons, with an investment of RMB 250 million[11]. - The subsidiary's share transfer to become a wholly-owned subsidiary is completed, which will not affect the consolidated financial statements[11]. - The company plans to continue focusing on project implementation and market expansion strategies in the upcoming quarters[11].